These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 35099304)

  • 1. Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells
    Song HY; Xia JS; Chen YG; Chen L
    Hum Exp Toxicol; 2022; 41():9603271221080236. PubMed ID: 35099304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells
    Song HY; Xia JS; Chen YG; Chen L
    Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S646-S653. PubMed ID: 34784831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific CYP450 Genotypes in the Chinese Population Affect Sorafenib Toxicity in HBV/HCV-associated Hepatocellular Carcinoma Patients.
    Guo XG; Wang ZH; Dong W; He XD; Liu FC; Liu H
    Biomed Environ Sci; 2018 Aug; 31(8):586-595. PubMed ID: 30231963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK.
    Chen Y; Pan B; Qiu J; Chen Z; Wang X; Tang N
    Toxicol In Vitro; 2021 Oct; 76():105226. PubMed ID: 34293431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient.
    Ye L; Yang X; Guo E; Chen W; Lu L; Wang Y; Peng X; Yan T; Zhou F; Liu Z
    PLoS One; 2014; 9(5):e96664. PubMed ID: 24797816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OATP1B1 Plays an Important Role in the Transport and Treatment Efficacy of Sorafenib in Hepatocellular Carcinoma.
    Wen J; Zhao M
    Dis Markers; 2021; 2021():9711179. PubMed ID: 34721737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP3A5 is unlikely to mediate anticancer drug resistance in hepatocellular carcinoma.
    Lauschke VM; Nordling Å; Zhou Y; Fontalva S; Barragan I; Ingelman-Sundberg M
    Pharmacogenomics; 2019 Oct; 20(15):1085-1092. PubMed ID: 31588878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer.
    Leskelä S; Honrado E; Montero-Conde C; Landa I; Cascón A; Letón R; Talavera P; Cózar JM; Concha A; Robledo M; Rodríguez-Antona C
    Endocr Relat Cancer; 2007 Sep; 14(3):645-54. PubMed ID: 17914095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
    Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
    BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporary decrease in tacrolimus clearance in cytochrome P450 3A5 non-expressors early after living donor kidney transplantation: Effect of interleukin 6-induced suppression of the cytochrome P450 3A gene.
    Enokiya T; Nishikawa K; Hamada Y; Ikemura K; Sugimura Y; Okuda M
    Basic Clin Pharmacol Toxicol; 2021 Mar; 128(3):525-533. PubMed ID: 33248001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
    Herraez E; Lozano E; Macias RI; Vaquero J; Bujanda L; Banales JM; Marin JJ; Briz O
    Hepatology; 2013 Sep; 58(3):1065-73. PubMed ID: 23532667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
    Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
    BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases.
    Jin M; Gock SB; Jannetto PJ; Jentzen JM; Wong SH
    J Anal Toxicol; 2005 Oct; 29(7):590-8. PubMed ID: 16419387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal clodronate combined with Cisplatin or Sorafenib inhibits hepatocellular carcinoma cell proliferation, migration and invasion by suppressing FOXQ1 expression.
    Zhou Y; Chen Y; Ma C; Shao B; Zhang F
    Cell Mol Biol (Noisy-le-grand); 2020 Apr; 66(1):49-54. PubMed ID: 32359383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the impact of CYP3A polymorphisms on the formation of α-hydroxytamoxifen and N-desmethyltamoxifen in human liver microsomes.
    Mugundu GM; Sallans L; Guo Y; Shaughnessy EA; Desai PB
    Drug Metab Dispos; 2012 Feb; 40(2):389-96. PubMed ID: 22096084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
    Chen Y; Feng F; Gao X; Wang C; Sun H; Zhang C; Zeng Z; Lu Y; An L; Qu J; Wang F; Yang Y
    Curr Cancer Drug Targets; 2015; 15(3):176-87. PubMed ID: 25714700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.
    Tang PF; Zheng X; Hu XX; Yang CC; Chen Z; Qian JC; Cai JP; Hu GX
    Drug Des Devel Ther; 2020; 14():5129-5141. PubMed ID: 33262574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma.
    Tang J; Sui CJ; Wang DF; Lu XY; Luo GJ; Zhao Q; Lian QY; Jeong S; Lin XM; Zhu YJ; Zheng B; Wu R; Wang Q; Liu XL; Liu JF; Xia Q; Wu G; Gu J; Wang HY; Chen L
    Theranostics; 2020; 10(12):5384-5397. PubMed ID: 32373219
    [No Abstract]   [Full Text] [Related]  

  • 20. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.